











































GISCOME – Genetics of Ischaemic Stroke Functional Outcome
network: A protocol for an international multicentre genetic
association study
Citation for published version:
Maguire, JM, Bevan, S, Stanne, TM, Lorenzen, E, Fernandez-cadenas, I, Hankey, GJ, Jimenez-conde, J,
Jood, K, Lee, J, Lemmens, R, Levi, C, Norrving, B, Rannikmae, K, Rost, N, Rosand, J, Rothwell, PM, Scott,
R, Strbian, D, Sturm, J, Sudlow, C, Traylor, M, Thijs, V, Tatlisumak, T, Wieloch, T, Woo, D, Worrall, BB,
Jern, C & Lindgren, A 2017, 'GISCOME – Genetics of Ischaemic Stroke Functional Outcome network: A
protocol for an international multicentre genetic association study', European Stroke Journal.
https://doi.org/10.1177/2396987317704547
Digital Object Identifier (DOI):
10.1177/2396987317704547
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.








GISCOME- Genetics of Ischemic Stroke Functional Outcome 
network: A protocol for an international multicentre genetic 
association study  
 
 
Journal: European Stroke Journal 
Manuscript ID ESO-16-0137.R1 
Manuscript Type: Protocol 
Date Submitted by the Author: 27-Feb-2017 
Complete List of Authors: Maguire, Jane; University of Technology Sydney Faculty of Health 
Bevan, Steve; University of Lincoln, Joseph Banks Laboratories  
Stanne, Tara; Goteborgs universitet Sahlgrenska Akademin 
Lorentzen, Erik; Goteborgs universitet Sahlgrenska Akademin, 
Bioinformatics Core Facility 
Cadenas, Israel; Vall d'Hebron Institut de Recerca, Mediterranean building 
Neurovascular Research Lab 
Hankey, Graeme J.; University of Western Australia, School of Medicine 
and Pharmacology 
Jimenez-Conde, Jordi; Institut Hospital del Mar d’Investigació Mèdica, 
Department of Neurology 
Jood, Katarina; Goteborgs universitet Sahlgrenska Akademin 
Lee, Jin-Moo; Washington University in Saint Louis School of Medicine, 
Cerebrovascular Disease 
Lemmens, Robin; Katholieke Universiteit Leuven, Laboratory for 
Neurobiology (Vesalius Research Center) 
Levi, Christopher; University of Newcastle Priority Research Centre for 
Brain and Mental Health Research John Hunter Hospital 
Norrving, Bo 
Rannikmae, Kristiina ; University of Edinburgh 
Rost, Natalia; Harvard University 
Rosand, Jonathan; Massachusetts General Hospital, Neurology; Harvard 
Medical School 
Rothwell, Peter; University of Oxford 
Scott, Rodney; University of Newcastle 
Strbian, Daniel; University of Helsinki 
Sturm, Jonathan; University of Newcastle, Faculty of Health and Medicine 
Sudlow, Cathie; University of Edinburgh, Centre for Clinical Brain Sciences 
Traylor, Matthew; King's College London School of Medical Education 
Thijs, Vincent ; Austin Health 
Tatlisumak, Turgut; University of Gothenburg, Neurology 
Wieloch, Tadeusz ; Lunds Universitet, Faculty of Medicine 
Woo, Dan; University of Cincinnati 
Worrall, Bradford; University of Virginia 
Jern, Christina; Goteborgs universitet Sahlgrenska Akademin 
Lindgren, Arne; Skanes universitetssjukhus Lund Hematologiska kliniken, 
Department of Neurology and Rehabilitation Medicine  
Keywords: stroke, stroke recovery, genetic association, GWAMAS, functional outcome 
The linked image cannot be  
displayed.  The file may have been  
moved, renamed, or deleted. Verify  






Introduction: Genome-wide association (GWA) studies have identified 
several novel genetic loci associated with stroke risk, but how genetic 
factors influence stroke outcome is less studied. The Genetics of Ischemic 
Stroke Functional outcome (GISCOME) network aims at performing genetic 
studies of stroke outcome. We here describe the study protocol and 
methods basis of GISCOME.  
Methods: The GISCOME network has assembled patients from 12 ischemic 
stroke (IS) projects with genome-wide genotypic and outcome data from 
the International Stroke Genetics Consortium (ISGC) and the National 
Institute of Neurological Diseases Stroke Genetics Network (SiGN) 
initiatives. We have assessed the availability of baseline variables, outcome 
metrics and time-points for collection of outcome data.  
Results: We have collected 8831 IS cases with genotypic and outcome 
data. Modified Rankin score (mRS) was the outcome metric most readily 
available. We detected heterogeneity between cohorts for age and initial 
stroke severity (according to the NIH Stroke Scale), and will take this into 
account in analyses. We intend to conduct a first phase GWA outcome 
study on IS cases with data on initial stroke severity and mRS within 60-
190 days. To date, we have assembled 5762 such cases and are currently 
seeking additional cases meeting these criteria for second phase analyses.  
Conclusion: GISCOME is a unique collection of IS cases with detailed 
genetic and outcome data providing an opportunity for discovery of genetic 
loci influencing functional outcome. GISCOME will serve as an exploratory 
study where the results as well as the methodological observations will 
provide a basis for future studies on functional outcome. GISCOME can also 
be used for candidate gene replication or assessing stroke outcome non-
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Introduction: Genome-wide association (GWA) studies have identified several novel genetic 
loci associated with stroke risk, but how genetic factors influence stroke outcome is less 
studied. The Genetics of Ischemic Stroke Functional outcome (GISCOME) network aims at 
performing genetic studies of stroke outcome. We here describe the study protocol and 
methods basis of GISCOME. 
Methods: The GISCOME network has assembled patients from 12 ischemic stroke (IS) 
projects with genome-wide genotypic and outcome data from the International Stroke 
Genetics Consortium (ISGC) and the National Institute of Neurological Diseases Stroke 
Genetics Network (SiGN) initiatives. We have assessed the availability of baseline variables, 
outcome metrics and time-points for collection of outcome data. 
Results: We have collected 8831 IS cases with genotypic and outcome data. Modified Rankin 
score (mRS) was the outcome metric most readily available. We detected heterogeneity 
between cohorts for age and initial stroke severity (according to the NIH Stroke Scale), and 
will take this into account in analyses. We intend to conduct a first phase GWA outcome 
study on IS cases with data on initial stroke severity and mRS within 60-190 days. To date, 
we have assembled 5762 such cases and are currently seeking additional cases meeting these 
criteria for second phase analyses.  
Conclusion: GISCOME is a unique collection of IS cases with detailed genetic and outcome 
data providing an opportunity for discovery of genetic loci influencing functional outcome. 
GISCOME will serve as an exploratory study where the results as well as the methodological 
observations will provide a basis for future studies on functional outcome. GISCOME can 
also be used for candidate gene replication or assessing stroke outcome non-genetic 
association hypotheses. 



































































Globally, stroke is one of the principal causes of adult disability and the global burden of 
stroke is increasing (1, 2). After 1 year, up to 28% of stroke survivors are dependent on others 
for help with self-care and personal activities of everyday living (3). Even though last decades 
have shown significant reductions in stroke incidence in high-income countries, this has not 
been observed in low- or middle-income countries and with population aging and improved 
stroke survival, the absolute number of people who survive a stroke and experience varying 
levels of impairment continues to rise (1, 2). A deeper understanding of the biology of 
recovery after stroke is needed to identify new therapeutic targets for this affected group of 
patients.   
 
Animal models demonstrate that following an acute ischaemic insult, the brain undergoes 
spontaneous recovery, repair, and remodelling (4). However, efforts to translate these findings 
to improve stroke outcomes in the clinical setting have been limited. Furthermore, the 
difficulty of predicting individual outcome poses a substantial challenge for ongoing post-
stroke management strategies. Clinical parameters related directly to the acute event, such as 
age, stroke severity, etiologic stroke subtype, infarct size and location are predictors of 
outcomes (5-9), but predictive models based on these factors are imprecise (10-12). Other 
prognostic factors may include socioeconomic and social factors, post-stroke depression, and 
type and degree of treatment and rehabilitation (13) and there is a need for consensus on 
description of rehabilitation measures (14). Improvement of neurological function following 
the initial event is likely dependent on several of the above mentioned factors combined with 
environmental and genetic influences (15). 
A genetic role in disease risk and susceptibility has been reported for many complex diseases 
including stroke (16-18), but the contribution of genetic factors to stroke outcomes is less 


































































clear. There is substantial heritability reported for both intracerebral haemorrhage (ICH) and 
ischemic stroke (IS) (15, 19, 20). Preliminary evidence from individual candidate gene studies 
suggests that the functional outcome after stroke may also be determined by genetic factors in 
addition to clinical factors (21-25), however replication in larger cohorts is still outstanding. 
Genome wide association studies (GWASs) use designs that are hypothesis generating and 
have led to discovery of disease-associated loci across multiple phenotypes and subsequent 
new knowledge of genetic architecture of diseases (26). The Genetics of Ischemic Stroke 
Functional outcome (GISCOME) effort therefore aims at detecting and describing genetic 
factors influencing IS outcomes, using data from already performed GWASs.  
 
Here we describe the creation of the GISCOME network as the first international multi-centre 
collection of IS cases with data on outcomes, genome-wide genotypes, and salient baseline 
variables and the study protocol for future genetic analysis. We include a description of the 










































































Twelve centers or joint projects have agreed to participate and provide data for analysis 
(Supplementary Table 1) and are already contributing to the International Stroke Genetics 
Consortium and the NINDS-SiGN Consortium efforts studying genetics of stroke risk. Some 
centers contributed more than one cohort of patients (eg. Barcelona) and some centers used 
multiple genotyping platforms (eg. Boston). This resulted in a total of 18 cohorts for which 
baseline characteristics, data availability and genotyping platform are outlined in 
Supplementary Table 1. The majority of the cohorts were hospital based with detailed 
phenotyping, including imaging. Supplementary Table 2 describes inclusion, recruitment 
period, and follow-up methods for each cohort. We have retrospectively collected phenotype 
data available for the 18 cohorts, selecting variables as outlined below. 
 
Process of variable selection 
The variables considered for inclusion in our study had already been collected in the 
individual cohorts by use of different study protocols. We conducted an initial survey across 
the cohorts to ascertain: 1) time-points when information on functional outcomes had been 
recorded; 2) what outcome measures had been utilised; and 3) all accessible baseline 
variables. We sought information on factors known or suspected to influence outcomes and 
these included: age, sex, living situation, stroke severity measured by National Institute of 
Health Stroke Scale (NIHSS) (26), ischemic stroke subtype, medical history/comorbid 
conditions, risk factors (including prior stroke or transient ischemic attack, coronary artery 
disease, atrial fibrillation, diabetes mellitus, hypertension, hyperlipidaemia, smoking, and 
alcohol use), pre-stroke physical functioning (measured with pre-stroke modified Rankin 
Score (mRS)), medications, and impairments and consequences of stroke such as cognitive 


































































impairment and depression (27). We identified 71 variables and grouped them into: (1) 
Demographics, (2) Baseline characteristics, (3) Pre-stroke characteristics, (4) Risk factors, (5) 
Post-stroke treatments, (6) and Outcome measures. This provided us with a comprehensive 
overview of all variables available in at least one of the cohorts.  
 
Next, we dropped the variables with unavailable data in more than one third of subjects. We 
selected modified Rankin Scale (mRS) score (27, 28) at 60-190 days as the most readily 
available functional outcome variable, after having observed that the majority of mRS values 
had been collected at 90 days +/- 2 weeks (81%) and that most of the remaining mRS 
observations were within the 60-190 day time span. The mRS values had already been scored 
by trained assessors at face-to-face or telephone follow-up for the majority of cohorts (for 
cohort specific details, please see Supplementary Table 2). The Lund Stroke Register and the 
Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS) phase 2 cohorts patients had 
been assessed with data from the 3 month follow up in the Swedish National Register 
Riksstroke. A validated algorithm for transforming answers on Riksstroke outcome questions 
into mRS grades was used even though this method prevented a differentiation between the 
mRS grades 0,1,2 (29). Baseline NIHSS was the selected measure for initial stroke severity. 
When multiple NIHSS scores were available we selected the score taken as close to 24 hours 
after stroke onset as possible (within 0-10 days).  
 
Availability of ischemic stroke subtype classification data measured by Trial of ORG 10172 
in Acute Stroke Treatment (TOAST) (30), Causative Classification System (CCS) (31, 32) or 
both, varied across the studies. Agreement between TOAST and CCS subtyping has been 
previously determined (31, 33) and there is significant genetic overlap between these two 


































































methods (34) which suggests pooling cases with either classification may be beneficial in 
subsequent GISCOME studies.  
 
Following this selection process, the phenotypic and genotypic data for each cohort were 
uploaded to central FTP secure servers located in Cambridge, UK, providing access to 
computational packages and file storage for this large-scale study. Further interrogation of the 
dataset led to a decision to remove additional variables not having a clear and homogeneous 
definition between cohorts or less than 50% availability. This included e.g. pre-stroke living 
and housing situation, ICH transformation after tPA, stroke to death interval, and recurrent 
stroke (Supplementary Table 3).  
 
Meta-Analysis plan 
Several assumptions were made by investigators and included consideration of the 
retrospective data from multiple cohorts and the subsequent limitations introduced by this. 
Thus, our planned analyses are considered as exploratory analyses to inform future 
prospective studies. We plan to analyse the primary outcome as mRS within the 60-190 days 
window, using first binary and then ordinal scales. The binary analyses will include both mRS 
0-2 vs 3-6 and mRS 0-1 vs 2-6. For the analyses of mRS as an ordinal variable, ordinal 
logistic regression will be used. Simulated power calculations based on the currently available 
data are depicted in the Supplemental Figure. The ordinal model provides greater power. In 
this model with the available data set, the minimal odds ratios detectable at 80% power with a 
p-value < 5 x 10
-8
, are 1.15 for MAF 30%, 1.24 for MAF 10% and 1.35 for MAF 5%.  Age, 
sex and initial NIHSS score are known to affect post-stroke outcome. To determine whether 
the expected associations were present in our data we performed regression analyses. As 
expected, all 3 of these variables were highly significant predictors of outcome in all 3 mRS 


































































models described above (Supplementary Table 4). Therefore, in all analyses we will adjust for 
age and sex, and subsequently adjust for baseline NIHSS. We will adopt a standard GWAS 
significance threshold of 5 x 10
-8
 for all primary analyses. Because outcome results may 
depend on when evaluated after stroke onset we intend to do a sensitivity analysis for the 
majority group of our subjects with mRS outcome data available at 90 days +/- 2 weeks 
(81%). A separate secondary analysis including only subjects with baseline NIHSS available 
within 0-1 days is also planned.  
 
Results 
Characteristics of the GISCOME collection 
We assembled a total of 8831 IS cases with phenotypic and genotype information in 
GISCOME. There were slightly fewer women (41.2%) than men, and cardiovascular risk 
factor frequencies were as expected in a stroke event group (Table 1). All cases included were 
of European ancestry and all cases were ≥18 years of age. Across all sites, stroke severity 
recorded at baseline were often mild strokes (NIHSS median 3; interquartile range (IQR), 1-
7). Stroke severity was similar across the included cohorts, with the exception of three 
cohorts: VISP (median NIHSS 1, Interquartile range (IQR) 0-2); Val de Hebron-1 (median 
NIHSS 17, IQR 11-20); and Washington University (median NIHSS 8, IQR 4-12). It is of 
note that the median time of NIHSS scores for VISP were 70 days (IQR, 45-98). As only 
0.3% of VISP fulfilled the NIHSS time window criteria of 0-10 days, this data set will not be 
included in the primary analysis.  The distribution of TOAST subtypes was as follows: 
cardioembolic (CE) stroke 31.7%, large artery atherosclerotic (LAA) 17.9%, small vessel 
disease (SVD) 19.2%, other and undetermined 30.2% (Table 1).  For CCS classification the 
distribution was: CE stroke 33.9%, LAA 16.4%, SVD 12.3% and other/underdetermined 
37.4%. Loss to follow up ranged from 0-21% with the exception of the Massachusetts 


































































General Hospital Genes Affecting Stroke Risk and Outcomes Study (MGH-GASROS) study 
(69% loss to follow-up ) (Supplementary Table 2). The Edinburgh cohort subjects will not be 
included in the primary analysis because >90% lacked mRS outcome data within the 60-190 
day window. 
 
GISCOME subjects to be included in primary analyses 
Given the considerations discussed above and the time windows selected for the primary 
GWA analysis (mRS day 60-190; NIHSS day 0-10), 5762 individuals from 16 cohorts are 
available with mRS, NIHSS and genotyping data for the primary analyses. Characteristics of 
this data set are summarized in Table 2. We intend to use the current dataset to conduct the 
first phase GWAS and then to expand to the second phase of this effort with data we expect to 
obtain from new cases from our existing studies and joint projects as well as from new 
contributing studies. A minimum set of variables required for phase 2 will include age, sex, 
stroke severity at 0-10 days and mRS at 60-190 days and available GWAS or DNA. Apart 
from the GWAS, we anticipate to specifically investigate known and putative genetic 
determinants of stroke outcome that include but are not limited to APOE and BDNF, both to 
validate these candidates and to demonstrate the viability of our cohort to replicate existing 
literature. We also plan to conduct the first GWAS based assessment for heritability of stroke 
outcome using a GWAS trait analysis approach using methods similar to those previously 
described regarding stroke risk (19). Insufficient sample size currently prevents the conduct of 
detailed subtype analyses at this stage, however we continue to seek additional cohorts to 
address this. 
Discussion 
This study protocol describes the GISCOME network which aims at conducting the first 
international multicentre large-scale GWAS on post-stroke outcomes. Within the GISCOME 


































































cohorts, the most commonly used outcome metric was the mRS. Fortunately, this is one of the 
preferred functional outcome measures of choice in contemporary stroke trials (27). The mRS 
demonstrates strong test-retest and moderate inter-rater reliability which may possibly be 
enhanced by structured interviews and training (35-37).  The clinical sensitivity or meaningful 
responsiveness to change in different outcome measures has been extensively studied (36). 
While mRS may not be the most sensitive scale to changes in functional activity, a one-point 
change in the scale is deemed to be clinically significant based on the range of activities 
captured by the scale (36). 
 
Notably, the timing of outcome measures is equally important to the determination of 
outcome as the measure itself.  By introducing time into consideration of outcome, two 
important derivative metrics emerge—the rate of change in outcome (rate of “recovery”), and 
maximal extent of outcome (extent of “recovery”). Rate of recovery refers to improvement 
per time unit. Extent of recovery refers to the functional ability, assessed by a metric such as 
mRS that captures the degree of functional ability. The biologic mechanism that underpins 
both of these is not well understood. However, because outcome metrics were not uniformly 
collected in several cohorts within GISCOME, we cannot currently study the rate of recovery. 
Improvement in functional outcome occurs most rapidly in the first days to weeks after 
ischemic brain injury; however, over the ensuing months, the degree of improvement plateaus 
(38). We chose to define mRS to encompass 60-190 days, but acknowledge that it is possible 
that some functional recovery may occur at earlier or later time points and this may not be 
accounted for in this investigation. The sensitivity analysis we propose will serve to determine 
how this may affect our results. 
 


































































We selected age, sex, and initial stroke severity (as measured by baseline NIHSS within 0-10 
days) as covariates in this analyses based on previous reports and our own observation that 
these variables influence functional outcome post-stroke. Study cohort also needs to be 
considered due to potential variability in outcomes due to differences in clinical practice 
specific to each stroke care system at the individual study sites. Other known determinants of 
post-stroke outcomes including pre-morbid status, acute stroke interventions (i.e., intravenous 
thrombolysis), neuroimaging characteristics of stroke (i.e., infarct size and location) will most 
likely not be included in this analysis due to lack of current data availability; however, 
ongoing studies within the ISGC such as MRI-GENIE (39) and TOTO (40) aim to provide 
additional information as to the role of specific stroke-related characteristics on genetics of 
functional outcomes in the future. 
 
Our study has several strengths. We have assembled the largest sample of detailed stroke 
outcome phenotypic and genotypic data.  The GISCOME network and proposed study will 
add to the understanding of genetic variants associated with neurological outcomes after the 
acute phase of ischemic stroke using individual level genetic data. Our retrospective design is 
largely pragmatic, taking advantage of existing datasets collected to examine stroke risk. The 
driving aim of GISCOME is to meta-analyse individual level data and identify novel genetic 
variants that influence the mechanistic pathways of functional outcomes post stroke. This 
parallels the efforts of other international consortia, several of which have extended the initial 
aim of identifying genetic risk factors associated with complex neurological disease to the 
investigation of genetic determinants of outcome e.g. Parkinson’s Disease (41).   
 
The retrospective design is a clear limitation, and introduces both selection and attrition bias 
since data included were previously collected under a variety of study protocols over a broad 


































































time frame with notable loss to follow up in some cohorts. We thus had to derive our 
phenotypic data set from these heterogeneous sources. We selected the mRS at 60-190 days 
post index stroke as the primary outcome measure based on availability, and this metric is 
both acceptable and reliable in clinical stroke research (28, 35-37). However, while the mRS 
is widely acknowledged as the standard outcome measure in stroke clinical trials, we accept it 
is a relatively crude measure of functional recovery and the timing of mRS collection was not 
consistent across all contributing datasets. Even though data about mortality among the 
included subjects is available for the time of the primary outcome evaluation (i.e. as close to 
90 days as possible), we do not have details about at the exact time point when deaths 
occurred. There was also heterogeneity between the individual cohorts regarding age and 
initial stroke severity and our total study sample has a bias towards milder strokes with 
median NIHSS of 3 which may hamper the detection of factors influencing the outcome in 
subjects with more severe stroke symptoms. We lacked data and/or clear definitions on 
several clinical variables known to influence outcome such as co-morbid depression, use of 
particular drugs e.g. selective serotonin reuptake inhibitors or anticonvulsants, and measures 
of social support (Supplementary Table 3). We also lack data on the volume of infarct, but as 
infarct volume is known to correlate with NIHSS we will be able to partly account for this. 
Finally, all cases were of European ancestry and do not represent a global stroke population. 
Therefore, specific genetic factors influencing outcome after stroke in subjects with other 
ethnic backgrounds will not be detected. We aim to address this in future efforts. In phase 2 
we will seek and invite sites that are derived from more diverse ethno-geographic groups. In 
the future, an expansion of the number of study subjects is also needed to improve the power 
of detecting genetic variants related to ischemic stroke outcome. Despite these limitations, a 
major strength of our planned analysis is the detailed description of the methods used and 


































































careful selection of a much needed repository for novel investigation into genetic 
determinants of stroke outcome.  
Conclusion 
The GISCOME study protocol describes an exploratory effort providing an excellent 
opportunity to detect genetic influence on stroke outcomes and to inform future studies within 
this important field of stroke research. The GISCOME sample size will increase through 
identification of additional sites and recruitment of cases within existing studies. We 
anticipate that this will increase our capability to explore other avenues of inquiry, for 
example, variants of smaller effect sizes. 
 We also strongly advocate for future prospective cohorts to utilize measures of functional 
capacity, quality of life, and neuropsychological function. We therefore urge the stroke 
community to characterize stroke cases using standardised definitions (42) and follow up 
stroke patients in their acute and rehabilitation phases with consistent documentation of 
functional ability. Co-operation within e.g. the International Stroke Genetics Consortium is an 
effective method to increase the availability of studies for this type of research. These efforts 
will provide a stable platform for identifying genetic variants that are associated with 
functional outcome.  
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Table 1   Characteristics of the 18 GISCOME cohorts 
Characteristics Ischaemic stroke cases 
(number = 8831) 
Missing data 
number (%) 
   
mRS available (60-190d), number (%) 7416 (84.0) 1415 (16.0) 
          mRS taken at day, median (IQR) 90 (81-90)  
Sex, female number (%) 3658 (41.4) 0 (0) 
Age, years mean (SD) 68.4 (13.5) 0 (0) 
NIHSS available (0-10d), number (%)** 6820 (77.2) 2011 (22.8) 
          NIHSS, median (IQR) 3 (1-7)  
          NIHSS taken at day, median (IQR) 0 (0-1)  
Rehabilitation measures registered, number/available (%) 1638/3387 (48.4) 5444 (61.6) 
TOAST Stroke subtypes, number/available (%)    
         Cases with TOAST data  6437 (72.9) 2394 (27.1) 
         Large artery atherosclerosis  1155/6437 (17.9)  
         Cardioembolic  2038/6437 (31.7)  
         Small vessel disease  1235/6437 (19.2)  
         Other/undetermined  2009/6437 (31.2)  
CCS Stroke subtypes, number/available (%)   
         Cases with CCS data  4694 (53.2) 4137 (46.8) 
         Large artery atherosclerosis  770/4694 (16.4)  
         Cardioembolic  1593/4694 (33.9)  
         Small vessel disease  576/4694 (12.3)  
         Other/undetermined  1755/4694 (37.4)  
Cardiovascular risk factors, number/available (%)*   
         Hypertension  5891/8787 (67.0) 44 (0.5) 
         Hypercholesterolemia  4715/8530 (55.3) 301 (3.4) 
         Diabetes mellitus  1940/8622 (22.5) 209 (2.4) 
         Atrial fibrillation  1746/8799 (19.8) 32 (0.4) 
         Ischaemic Heart Disease 1589/7474 (21.3) 1357 (15.4) 
         Current smoker  2007/8683 (23.1) 148 (1.7) 
Pharmacological intervention,    
         Cases treated with Alteplase, number/available (%) 689/4886 (14.1) 3945 (44.7) 
Premorbid impaired functional status, number (%) 772/6867 (77.8) 1964 (22.2) 
Pre-stroke living situation, number/available (%)  6095 (69) 
         Alone  897/2736 (32.8)  
         Divorced  64/2736 (2.3)  
         Widowed  17/2736 (0.6)  
         With someone  1758/2736 (64.3)  
First or recurrent stroke, number/available (%)  477 (5.4) 
         First  6797/8354 (81.4)  
         Recurrent  1557/8354 (18.6)  
Pre-stroke housing, number/available (%)  6430 (72.8) 
          Assisted living  5/2401 (0.2)  
          Institution  55/2401 (2.3)  
          Nursing home 13/2401 (0.5)  
          Own house/flat 2318/2401 (96.5)  
          Other  10/2401 (0.4)  
* Availability across cohorts. Numbers vary per cohort. 
** Only n=5/1723 (0.3%) of individuals in VISP fulfilled the NIHSS time window criteria of 0-10d. 
mRS indicates modified Rankin Scale; IQR, interquartile range; SD, standard deviation; NIHSS, NIH stroke scale; TOAST, 
Trial of Org 10172 in Acute Stroke Treatment stroke sub classification; CCS, Causative Classification System 


































































Table 2.  The mRS distribution of ischaemic stroke patients in 60-190 day window for GISCOME 





Ischaemic stroke cases 
(number = 5762) 
14 cohorts* 
Ischemic stroke cases 
(number = 4421) 
   
Sex, females number (%) 2472 (42.9) 1894 (42.8) 
Age, years mean (SD) 68.6 (14.0) 68.7 (13.9) 
   
mRS dichotomized 0-2 vs 3-6    
          Poor outcome, number (%) 2131 (37.0) N/A 
mRS dichotomized 0-1 vs 2-6   
          Poor outcome, number (%) N/A 2567 (58.1) 
mRS, ordinal scale   
          0 718 (12.5) 718 (16.2) 
          1 1953 (33.9) ** 1136 (25.7) 
          2  960 (16.7) 960 (21.7) 
          3 847 (14.7) 628 (14.2) 
          4 605 (10.5) 479 (10.8) 
          5 215 (3.7) 138 (3.1) 
          6 464 (8.1) 362 (8.2) 
 
NIHSS (0-10 days), median (IQR) 4 (2-9) 4 (2-9) 
          NIHSS taken at day, median (IQR) 0 (0-1) 0 (0-1) 
*LSR and SAHLSIS Phase 2 not included in this distribution because these cohorts used a collapsed 
score for mRS 0-2. **Including LSR and SAHLSIS phase 2, where collapsed mRS scores of 0-2 
(number=519 and number=298 subjects, respectively) are assigned as having mRS 1. SD indicates 
standard deviation; mRS, modified Rankin Scale, LSR, Lund Stroke Register; SAHLSIS, Sahlgrenska 




































































  Supplementary Table 1. Description and availability of data included in the 18 GISCOME cohorts.  
Center/ 
Joint project 




NIHSS at baseline  
(median [IQR]) 
Genotype platform mRS at 60-190  
days (%) 
Australia VIS 580 71.3 45.2 4 (2-8) Illumina 610Q 86.7 
Barcelona Hospital del Mar1 924 75.2 47 5 (3-12) Illumina 5M 98.1 
 Val de Hebron-1 170 73.0 52.4 17 (11-20) Illumina Omni1-Quad  77.1 
 Val de Hebron-2 105 68.2 25.7 3 (1.5-8) Illumina Omni2.5- Quad 100 
Boston MGH-GASROS 158 66.9 38.6 3 (1-9) Illumina 610Q 68.4 
 MGH-GASROS 169 68.7 46.7 3 (2-9) Affymetrix 6.0 29.0 
 MGH-GASROS1 527 64.5 35.9 3 (1-7) Illumina 5M 48.8 
Cincinnati GCNKSS
1
 372 69.4 44.9 4 (2-8) Illumina 5M 95.2 
Edinburgh The Edinburgh Stroke Study* 483 70.9 44.7 4 (1-7) Illumina 660Q 9.9 
Gothenburg SAHLSIS 261 59.3 41.8 3 (2-7) Illumina 750K 88.1 
 SAHLSIS1 797 54.6 33.4 3 (1-8) Illumina 5M 88.8 
Helsinki Helsinki-2000 Study 351 63.9 38.5 5 (2-10) Illumina CoreExome 100 
Leuven LSGS1 469 67.5 41.4 4 (2-8) Illumina 5M 97.7 
Lund LSR  528 74.3 47.7 3 (2-7) Illumina 750K 92.6 
 LSR
1
  574 71.5 44.9 4 (2-8) Illumina 5M 83.4 
Oxford Oxford Stroke Study 548 74.0 50.5 2 (0-4) Illumina 660Q 98.9 
Virginia VISP* 1723 68.0 35.0 1 (0-2) Illumina 1M 93.2 
Washington WASH-U1 92 67.2 43.5 8 (4-12) Illumina 5M 100 
*not included in the primary GISCOME analyses. 1Genotyped in the Stroke Genetic Network (SiGN) study. N indicates number; NIHSS, National 
Institute Health Stroke Scale; IQR, Interquartile Range ; mRS, modified Rankin score ; VIS, indicates Vascular Ischemia Study; MGH- GASROS, 
Massachusetts General Hospital Genes Affecting Stroke Risk and Outcomes Study; GCNKSS, Greater Cincinnati/ Northern Kentucky Stroke Study; 
SAHLSIS, Sahlgrenska Academy Study on Ischemic Stroke; LSGS, Leuven Stroke Genetics Study; LSR, Lund Stroke Register; VISP, Vitamin 
Intervention for Stroke Prevention study; WASH-U, Washington University Stroke Study. 
































































Supplementary Table 2. Description of design methods used in the 18 GISCOME cohorts.  
Center/  
Joint project 
Cohort(s) Age Range 
(years) 
Study Design 





Estimated loss  
to follow up 
Australia VIS >18  Hospital based 2003-2006 Telephone 15% 
Barcelona Hospital del Mar  
Val de Hebron-1 and -2 
All  
All  
Hospital based 2011-ongoing Telephone 0% 
Boston MGH- GASROS ≥18 Hospital based  2001-2011 Telephone 69% 
Cincinnati GCNKSS All  Population based  1993-2010 Face-to-face  15% 
Edinburgh The Edinburgh Stroke 
Study 
>18 Hospital based 2002-2005 Postal 
questionnaire 
5% 
Gothenburg SAHLSIS, phase 1 18-69 Hospital based 1998-2003 Face-to-face 5% 
Gothenburg SAHLSIS, phase 2 18-69 Hospital based 2004-2011 Riksstroke register 21% 
Helsinki Helsinki-2000 Study >18 Hospital based 2011- 
ongoing 
Face-to-face 0% 
Leuven LSGS ≥18 Hospital based 2008 Face-to-face 2.2% 
Lund LSR  ≥18 Hospital based 2001- 
ongoing 
Riksstroke register 12%   
Oxford Oxford Stroke Study All  Community based 2002-2004 Face-to-face  0% 
Virginia VISP  >35 Multi centre, double blind, 
RCT 
1996-2003 Face-to-face  6% 
Washington WASH-U >18  Hospital based* 2008-2013 Telephone 0% 
When a center used the same methods for several of their cohorts, these are collapsed to one row in this table. *Only patients with NIHSS at 
24hrs = 4-20 and Baseline mRS < 2 included. VIS indicates Vascular Ischemia Study; MGH- GASROS, Massachusetts General Hospital Genes 
Affecting Stroke Risk and Outcomes Study; GCNKSS, Greater Cincinnati/ Northern Kentucky Stroke Study; SAHLSIS, Sahlgrenska Academy 
Study on Ischemic Stroke; LSGS, Leuven Stroke Genetics Study; LSR, Lund Stroke Register; VISP, Vitamin Intervention for Stroke prevention; 
WASH-U, Washington University Stroke Study, NIHSS, NIH stroke scale. 
 
































































Supplementary Table 3. Variables considered for inclusion in the primary GWAS analyses for the 16 




    
Description Available* 
Demographics Age numerical (years) yes  
 Gender Female/male yes  
Pre-stroke 
characteristics 
Premorbid functional status Normal/impaired yes  
Serious comorbidity pre-stroke IHD or other/no no 
Living situation pre-stroke Alone/with someone no  
 Housing pre-stroke Own house or 
flat/institution 
no 
    
Baseline First/recurrent stroke First/recurrent yes  
 TOAST LAA, CE, SVD, UNK yes  
 CCS LAA, CE, SVD, UNK yes  
 NIHSS numerical  yes  
 tPA therapy in acute phase yes/no yes  
 ICH transformation after tPA 
treatment 
yes/no no  
 Recanalisation approximately 
1hour after tPA 
yes/no no  
Risk factors Hypertension yes/no yes  
 Diabetes mellitus yes/no yes  
 Current smoking yes/no/ex yes  
 Atrial fibrillation yes/no yes  
 Ischemic heart disease yes/no yes  
 Hypercholesterolemia yes/no yes  
Treatment post 
stroke 





Rehabilitation treatment yes/no yes  
SSRI or similar treatment yes/no no 
Outcome Interval between stroke and 
death 
numerical (days) no 
 Recurrent stroke yes/no no 
 Depression yes/no no 
 NIHSS at various time points numerical yes at baseline 
 mRS at various time points numerical yes at 3 months 
(60-190 days)  
 Glasgow Outcome Scale at 
various time points 
numerical no 
 Barthel Index at various time 
points 
numerical no 
*Variable having clear and homogeneous definitions between cohorts and available in at least 50% 
of subjects. GWAS indicates genome wide association study; IHD, ischaemic heart disease; TOAST, 
Trial of Org 10172 in Acute Stroke Treatment stroke sub classification; CCS, Causative 
Classification System; LAA, Large artery atherosclerosis; CE, Cardioembolic; SVD, Small vessel 
disease; UNK, Other/undetermined; NIHSS, NIH stroke scale; tPA, tissue plasminogen activator; 
ICH, intracerebral haemorrhage; SSRI, Selective serotonin reuptake inhibitor; mRS, modified 
Rankin Scale. 
































































Supplementary Table 4: Associations between age, sex and initial stroke severity (NIHSS) and functional outcome (mRS) 3 months 
after stroke in the GISCOME data.  
 
 mRS 0-2 vs 3-6 
OR (95% CI), P 
mRS 0-1 vs 2-6 
OR (95% CI), P 
Ordinal (0-6) 
OR (95% CI), P 
Age 1.06 (1.05-1.06), 1.6x10
-122
 1.03 (1.03-1.03), 2.5x10
-48
 1.04 (1.04-1.04), 1.4x10
-119
 
Sex (female) 1.72 (1.54-1.91), 1.1x10
-22
 1.55 (1.40-1.73), 1.6x10
-16
 1.68 (1.53-1.85), 9.7x10
-26
 
NIHSS (0-10d) 1.16 (1.15-1.17), 2.7x10
-184
 1.14 (1.13-1.15), 2.0x10
-119




mRS, modified Rankin Scale; OR, odds ratio; CI, confidence intervals. OR is for poor outcome per year for age, for females, and per 1 




































































Supplementary Figure. Simulated power calculations for genetic influence on functional 
outcome 3 months after stroke for a p-value < 5 x 10-8, based on the currently available data 
set.   
 
Blue indicates ordinal regression for 16 GISCOME cohorts (n= 5762); red indicates binary 
regression (mRS 0-2 vs 3-6) for 16 GISCOME cohorts (n= 5762); yellow indicates binary 
regression (mRS 0-1 vs 2-6) logistic regression for 14 GISCOME cohorts (n= 4421; LSR and 
SAHLSIS Phase 2 are not included in this distribution because these cohorts used a collapsed 
mRS score 0-2). Lines indicate simulated power for minor allele frequency (MAF) 0.3, open 
circles for MAF 0.1, and dashed line for MAF 0.05. The mRS was scored within a 60-190 
day window.  
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